Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice
- PMID: 10073729
- DOI: 10.1016/s0264-410x(98)00224-2
Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice
Abstract
The replicon of Semliki Forest virus (SFV) offers the possibility to direct high-level, transient expression of heterologous proteins in vivo. We initiated studies to determine the possibility of employing the SFV expression system for recombinant vaccine purposes. Mice immunized with recombinant SFV encoding Influenza A nucleoprotein (NP) or E. coli LacZ developed long-lasting antigen-specific IgG levels and induction of cytotoxic T-cell (CTL) memory that persisted for over one year. Predominantly type 1 T-helper cells were induced as shown by IgG subclass ELISA. Humoral and cell-mediated immune responses could be induced upon delivery by several administration routes and mucosal immunizations induced secretory IgA in the respiratory tract. Development of immune responses against the vector itself did not inhibit boost responses by subsequent immunizations with recombinant SFV. Immunization of mice with vectors encoding the Influenza A virus antigens nucleoprotein (NP) and hemagglutinin (HA) resulted in immune responses that were protective against challenge infection with Influenza virus.
Similar articles
-
Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus.Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3009-13. doi: 10.1073/pnas.92.7.3009. Proc Natl Acad Sci U S A. 1995. PMID: 7708765 Free PMC article.
-
Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein.J Gen Virol. 2001 Jul;82(Pt 7):1737-1747. doi: 10.1099/0022-1317-82-7-1737. J Gen Virol. 2001. PMID: 11413386
-
Self-replicating Semliki Forest virus RNA as recombinant vaccine.Vaccine. 1994 Dec;12(16):1510-4. doi: 10.1016/0264-410x(94)90074-4. Vaccine. 1994. PMID: 7879415
-
Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.J Virol. 1993 Oct;67(10):5843-8. doi: 10.1128/JVI.67.10.5843-5848.1993. J Virol. 1993. PMID: 7690411 Free PMC article.
-
Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.J Immunol. 2007 Jun 1;178(11):6761-9. doi: 10.4049/jimmunol.178.11.6761. J Immunol. 2007. PMID: 17513723
Cited by
-
Transfection of infectious RNA and DNA/RNA layered vectors of semliki forest virus by the cell-penetrating peptide based reagent PepFect6.PLoS One. 2013 Jul 8;8(7):e69659. doi: 10.1371/journal.pone.0069659. Print 2013. PLoS One. 2013. PMID: 23861978 Free PMC article.
-
Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.Future Virol. 2013 Jan 1;8(1):25-41. doi: 10.2217/fvl.12.122. Future Virol. 2013. PMID: 23440999 Free PMC article.
-
Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine.J Virol. 2007 Dec;81(24):13412-23. doi: 10.1128/JVI.01799-07. Epub 2007 Oct 3. J Virol. 2007. PMID: 17913817 Free PMC article.
-
Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.PLoS One. 2010 Sep 10;5(9):e12670. doi: 10.1371/journal.pone.0012670. PLoS One. 2010. PMID: 20844763 Free PMC article.
-
Role of innate signalling pathways in the immunogenicity of alphaviral replicon-based vaccines.Virol J. 2011 Jan 24;8:36. doi: 10.1186/1743-422X-8-36. Virol J. 2011. PMID: 21261958 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
